WuXi Biologics, the Chinese pharmaceutical manufacturer, has announced its partnership with Harbour BioMed, the biotechnology firm with operations in China, the US, and the Netherlands.
The two firms have formed a strategic collaboration to develop and manufacturer Harbour BioMed’s HCAb antibody.
WuXi Biologics will be responsible for supporting the supply of the antibody to be used in trials following the Investigational New Drug (IND) applications.
The end-to-end solutions firm will focus on the supply in China, where Harbour BioMed’s R&D site is located, as well as the rest of the world.
“In about a year's time, our scientists have moved our leading HCAb molecule into IND enabling stage,” remarked Harbour BioMed’s Chief Executive Officer, Dr. Jingsong Wang.
“We are excited to collaborate with WuXi Biologics to accelerate further development of this molecule.”
“This collaboration is aligned with our strategy to partner with industry leaders to bring forward innovative therapeutics that will help patients.”
“Harbour's trust in WuXi Biologics to develop this novel format of HCAb is a strong testament of WuXi Biologics as a global leader in technology,” stated Dr. Chris Chen, Chief Executive Officer of WuXi Biologics.
“We have enabled more than 20 complex molecules to the clinic including different bispecific formats, ADCs, fusion proteins and novel protein scaffolds,” he added.
“We aim to empower anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing.”